Agoracom Blog Home

Posts Tagged ‘Cannabis’

NORTHBUD $NBUD.ca – As Canada gears up for pot 2.0, more shortages are on the menu $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 12:07 PM on Thursday, October 3rd, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE
—————————–
  • Canada’s legalization of pot edibles later this year is facing an even more shambolic start than the dried flower market, which is still struggling to meet demand, according to industry players.

Kristine Owram, Bloomberg News

Canada’s legalization of pot edibles later this year is facing an even more shambolic start than the dried flower market, which is still struggling to meet demand, according to industry players.

“At least that time we knew what the permissible product types were going to be and were already making them in the medical context,” said cannabis lawyer Trina Fraser, a partner at Brazeau Seller Law in Ottawa.

Canada will add edibles, extracts and topicals to the list of legal cannabis products no later than Oct. 17. Many analysts agree these products will generate better demand and margins than dried flower. But the federal government has not yet issued regulations for the new formats, making it difficult for producers to prepare lest they unknowingly violate some rule.

A spokeswoman for Health Canada declined to comment on when the regulations will be released.

In addition, a huge licensing backlog has built up at Health Canada, the government agency that oversees cannabis regulations. About 614 applications were waiting in the queue as of March 31.

“A full rollout amongst a nice wide array of producers and a wide array of these new product types is going to take time, literally years, because we have such a licensing backlog,” Fraser said.

Company Stockpiling

Canada’s market for edibles and other alternative pot produces will eventually be worth C$2.7 billion ($2 billion) annually, but consumers should expect “missteps, delays and frustration” in the early days, Deloitte said in a report published Monday. Jennifer Lee, Deloitte Canada’s cannabis national leader, estimated it will be a minimum of 24 months before the industry normalizes.

In the meantime, many pot companies are stockpiling, choosing to forgo revenue today to ensure they have enough supply for the new high-value products. This is exacerbating the shortage of dried flower, but executives say it’s worth it.

“We’ve made a very conscious effort to delay revenue,” said Chuck Rifici, chief executive officer of Auxly Cannabis Group Inc. Selling into the market today doesn’t build brand recognition because shelves are empty and consumers are buying whatever’s available, he added. “I would much rather save that product, get a multiple of margin on that brand and make sure that I have enough inventory.”

Lab Delays

This is proving to be a boon for extraction companies like Valens GroWorks Corp. Valens has contracts with many of the biggest pot companies, including Canopy Growth Corp., Hexo Corp. and Tilray Inc., to extract cannabis oil from their plants, which is then used for products like edibles and vape cartridges. It’s also investing heavily in its testing labs in the belief that Health Canada will have stringent regulations to ensure pesticides and other contaminants don’t make it into the new consumer products.

“Even in labs today there’s delays where people are waiting three weeks to a month to get lab results back and I think that will only get worse,” said Everett Knight, Valens’ executive vice president of strategy and investments.

Companies are also making big bets on what products will be in demand, with Canopy and Hexo leaning toward cannabis beverages and others toward vaping.

Be Prepared

“Why do I want an edible or a drink when I can have a vape?” Irwin Simon, interim CEO of Aphria Inc., said in an interview on the sidelines of a cannabis conference last month. “I see the margins and the opportunities there.”

Rifici at Auxly also believes vape pens will be “the most important category by far.” But there are many unanswered questions. For example, will the government require companies to engrave its mandatory THC warning symbol into the pen itself, or will a sticker suffice?

This is why Valens is offering its customers 196 different options for its white-label vape pens. “You’ve got to make sure you cover your bases and prepare for all the possibilities,” Knight said.

Despite the uncertainty, it’s better to be prepared even if plans and production lines have to be tweaked once the regulations come out, said Bruce Linton, CEO of Canopy, which is building a 197,000 square foot bottling plant for cannabis beverages in Smiths Falls, Ontario.

“We’re in a situation where it’s better to spend money to be ready than to save money and be late,” he said.

 Cannabis Canada is BNN Bloomberg’s in-depth series exploring the stunning formation of the entirely new – and controversial – Canadian recreational marijuana industry. Read more from the special series here and subscribe to our Cannabis Canada newsletter to have the latest marijuana news delivered directly to your inbox every day.

Source: https://www.bnnbloomberg.ca/as-canada-gears-up-for-pot-2-0-more-shortages-are-on-the-menu-1.1268844

Benefits #CBD oil promotes for your health – SPONSOR: Empower Clinics $CBDT.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 12:03 PM on Wednesday, October 2nd, 2019

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics
  • Patient database of over 165,000 patients 
  • Platform generating $4MM USD in revenue annually (2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Launching CBD extraction facility
  • First extraction system capacity = 6,000 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025

Benefits CBD oil promotes for your health

CBD oil is a much talked about product, it is a topic of hot conversation, it is in the news and everyone has an opinion! Some opinions are based on fact, others on assumption and there are a group of people who just do not know what to think at all. This article will attempt to provide you with some information as to the possible health benefits which can be derived from taking CBD oil. CBD oil has much recent research attached and there is also increasing testimony from those who regularly take the product for a number of very different conditions from which they are suffering.

The first point to mention is that CBD or to give it its chemical name, Cannabidiol, should not be confused with its sister chemical THC or Tetrahydrocannabinol. Both chemicals are derived from the cannabis plant which in itself has over 100 chemicals and although the two chemicals are similar in a sense, they differ in the way in which their atoms are put together. Here, in the UK, CBD is legal to purchase whether it be as an oil or as part of another preparation.  It is the THC which is not legal and any product containing CBD can only contain trace elements of THC at the most, in fact products can contain no more than 0.2% THC. Each country has their own rules and so if you are planning to use CBD anywhere else other than in the UK, you should check the legal status first.

CBD is extracted from the cannabis plant using different processes and each manufacturer will use their own particular method of extraction. When the CBD has been extracted, it will then be mixed with a carrier oil and it is then known as CBD oil.

Many people have conditions which cause them to be in serious pain or have quite debilitating symptoms. Sometimes conditions can be treated and sometimes they cannot be treated and instead they are managed by medication, which is not the best solution for a long term problem. CBD has shown promise in giving relief and even turning around certain conditions. Evidence for its effectiveness has come in anecdotal form from those who have used the product and it comes also with scientific back up for many conditions and as more and more research emerges with results, CBD is becoming a go to product of choice for many. So what conditions is CBD oil known to help?

  • Chronic pain can be significantly lessened
  • Anxiety can be relieved
  • Depression
  • Stress
  • Both rheumatoid arthritis and osteoarthritis
  • Seizures including epilepsy
  • Inflammation
  • Nausea
  • Chronic headaches and migraines
  • MS
  • Parkinsons
  • Alzheimers
  • Obesity
  • Cancers

And the list goes on, in fact conditions throughout the body can be addressed using CBD oil.

It is not something that we are used to as when we are given ‘a pill for an ill’, we would not expect to receive the same pill for a headache and an infection for example, yet CBD would appear to treat and relieve many non similar conditions, the following provides an explanation as to why that is the case.

Our body is a complex series of structures which we have grouped into systems, we have the Nervous system, the Cardiovascular system, the Immune system and so on but one system which was only discovered around 30 years ago is the Endocannabinoid system. This system is the system which is responsible for bringing about an equilibrium or balance to the body, sometimes referred to as homeostasis. It does this via cannabinoid receptors. These receptors look for cannabinoids to attach to them and when they are satisfied that they have their requirement, the balance is restored and as long as the supply and uptake is maintained, so is the balance. When the system becomes unbalanced, the receptors are not fulfilled and when that balance is no longer there, illness and pain are felt. The body naturally produces its own endocannabinoids, sometimes it will not produce enough and sometimes the endocannabinoid being produced fail to reach the receptor points. CBD is a cannabinoid and it is thought that it works with the bodies own system to satisfy the receptors. This is why CBD can be used for all manner of illnesses and difficulties within the body. It can even be used in lower doses by healthy people to keep their system in check and many use it for this purpose.

Each person will have a dose that suits them best and it is up to each user to find that dose. It is always tempting to read about all of the good that a product has to offer and go about taking a high dose to try to access some of that good but this is the wrong way to go. Start with a small amount and gradually increase the amount until you feel a benefit. At that point, that should be the dose that suits you. Start with the weakest preparation and if you need to move to a stronger preparation, do that next. Do not assume that you will be able to copy the dose that someone else is taking, that is just not true, you have to work slowly to find your own.

Source: https://augustafreepress.com/benefits-cbd-oil-promotes-for-your-health/

#Coors $TAP Enters #CBD Market With New Distribution Deals – SPONSOR: NORTHBUD $NBUD.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 4:05 PM on Monday, September 30th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE
—————————–

Coors Enters CBD Market With New Distribution Deals

  • As CBD continues to hit fever pitch with consumers, Molson Coors Brewing Company is entering the business
  • Company recently inked distribution deals with Colorado’s Best Drinks and DRAM Apothecary.

Emily Cappiello Contributor 

As CBD continues to hit fever pitch with consumers, Molson Coors Brewing Company is entering the business. The company recently inked distribution deals with Colorado’s Best Drinks and DRAM Apothecary.

“We are very excited to add Colorado’s Best Drinks and DRAM to our portfolio, giving us the ability to offer amazing CBD hemp products to retailers and consumers in the Denver Metro area. We see a big demand for high quality and unique products in the non-alcoholic space and we think Colorado’s Best Drinks and DRAM are the perfect solution to fill that consumer demand,” says Jennifer DeGraff, director of marketing, Coors Distributing Company.

Moose Koons, co-owner of Colorado’s Best Drinks, explains that the process started about eight months ago when one of the company’s beverages ended up in the hands of someone at the company.

“We started the process from there and Coors really saw an opportunity,” he says. “Working with Coors is going to open up our distribution into restaurants, grocery, bars, convenience stores — they have a fantastic network. But it’s also about the validation and legitimacy of our organization. We’ve been selling CBD drinks for more than a year now.”

Koons explains that Colorado’s Best Drinks has worked closely with the Colorado Department of Health in order to figure out healthy CBD boundaries in consumables, which he feels is one of the reasons that Coors was drawn to the company.

Additionally, Koons adds that what makes Colorado’s Best Drinks different from other CBD-infused beverages out there is the fact that the company is hands-on in the manufacturing process.

“We understand how ingredients go together and how they bond. Sometimes, CBD can be tricky and may not want to blend, but we found solutions to make sure we are putting out a quality product,” he says.

As for teaming up with Coors as far as distribution, Koons says the company is poised for growth already, modeling its processes after the booming craft beer industry in Colorado.

“We watched the craft beer industry and we’ve been working on scalability for two or three years. We should be able to increase distribution without having to change the facility and we put a lot of processes and procedures in place already,” he says.

Currently, distribution will be limited to Colorado while the Food and Drug Administration irons out regulations regarding hemp-based food and beverages. However, Koons notes that continuing the education of the consumer will help to eliminate stigma, questions and concerns surrounding the growing food and beverage category.

“One of our goals is to continue to educate the consumer that hemp is fantastic. It’s sustainable and there are even receptors in your body that allow you to be able to process it. We are going to continue to try to really bring hemp into the spotlight,” he says.

Colorado’s Best Drinks offers a full line of sparkling beverages infused with broad spectrum hemp extract. Each flavor – Black Cherry, Cola, Ginger Ale, Lemonade and Root Beer – is crafted with just five ingredients: sparkling water, organic agave nectar, natural flavors, non-GMO citric acid, and broad spectrum hemp extract. Each 12oz BPA-free can contains 100 calories and are all vegan, gluten-free, non-GMO, and free of sodium and preservatives.

Source: https://www.forbes.com/sites/emilycappiello/2019/09/24/coors-enters-cbd-market-with-new-distribution-deals/#19e7012f4bc5

North Bud Farms $NBUD.ca – A Budding Industry: #CBD Statistics & Trends (Infographic) $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 5:09 PM on Friday, September 27th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE
—————————–

A Budding Industry: CBD Statistics & Trends (Infographic)

  • The sales of CBD are predicted to reach about $1.8 billion by 2022
  • At the moment, there are over 850 brands of CBD products in the US market
  • With over $1 billion, Colorado is the state with the highest cannabis revenues
  • Data on CBD user demographics show 40% of Americans are interested in trying CBD.

By Bojana Petkovic

What is CBD all about and why are cannabis and hemp oil all over the internet? To help you understand this rapidly growing industry, we’re going to present you with some interesting CBD statistics and facts.

CBD or cannabidiol is one of the most important active substances in the cannabis (marijuana) plant. It can be obtained from different cannabis species, but it can also be synthetically produced. There are divided opinions on whether it works better on its own or joined with other cannabis compounds, yet one thing is for sure — its positive effects on human (and pet) health are undeniable. At the moment, only CBD derived from hemp is legal under federal law while we wait for more research on the substance to begin.

We can observe CBD as an amazing cure, but we can also watch the changes in the industry. That is one serious venture and a lot of people would like to get a piece of that $20 billion pie (this is the prognosis for US sales of CBD by 2024).

With that in mind, here is our pick of:

Top 10 CBD Facts and Statistics

  • The sales of CBD are predicted to reach about $1.8 billion by 2022.
  • At the moment, there are over 850 brands of CBD products in the US market.
  • With over $1 billion, Colorado is the state with the highest cannabis revenues.
  • Data on CBD user demographics show 40% of Americans are interested in trying CBD.
  • A cannabis worker earns more than an average American.
  • The demand for employees in the CBD oil industry rose by 76% in one year.
  • Statistics on CBD direct sales show that the majority of direct sellers are women.
  • Women are founders or general managers of over 75% of CBD brands.
  • Pure CBD is perfectly safe for usage and you cannot get addicted to it.

See what we mean? Take a look at the following infographic for more mindblowing CBD trends.

Source: https://loudcloudhealth.com/cbd-statistics-infographic/

North Bud Farms $NBUD.ca – Global #Cannabis Infused Drinks Market Anticipated to Accelerate At 438% CAGR at the end of 2029 $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 11:31 AM on Monday, September 23rd, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE

Global Cannabis Infused Drinks Market Anticipated to Accelerate At 438% CAGR at the end of 2029

  • Global sales of cannabis infused drinks will surpass US$ 200 Mn in 2019, propelled by growing efficiencies in the delivery methods of drinkables, along with increasing discretion and social acceptance of the consumption method, in contrast to smoking cannabis.
  • Cannabis infused beer continues to account for leading shares of the market, approximately 80%, which can be attributed to the strong perception of leading beer brewers that intersection between cannabis-infused functional beverages and beer makes a good business sense.

Global sales of cannabis infused drinks will surpass US$ 200 Mn in 2019, propelled by growing efficiencies in the delivery methods of drinkables, along with increasing discretion and social acceptance of the consumption method, in contrast to smoking cannabis. Broader legalization of marijuana has led big alcohol producers to pivot to pot in the recent past. Cannabis infused beer continues to account for leading shares of the market, approximately 80%, which can be attributed to the strong perception of leading beer brewers that intersection between cannabis-infused functional beverages and beer makes a good business sense. The US will remain the leading market for cannabis infused drinks, as leading manufacturers focus on creating safer ways of ingesting cannabis for consumers, while the start-ups continue to scramble for capitalizing on demand through new range of cannabis-infused beverages. Canada is expected to be the high-growth market for cannabis infused drinks, with gains primarily driven by the recent federal legalization of marijuana.

What are the Key Growth Drivers of Cannabis Infused Drinks Market?

  • Manufacturers of cannabis infused drinks are putting more efforts for creating proper emulsification of THC, in a bid to achieve proper suspension within liquids and quicker uptake time – under 30 minutes. This falls in line with the consumer demand for faster feedback on their dosage, which in turn will favor sales of cannabis infused drinks. Leading beverage companies have taken notice of the ravenous appetite of consumers that exists inside the cannabis culture, thereby transitioning into cannabis infused drinks industry.
  • As recreational marijuana legalization continues to become a reality across more U.S. states, individuals have started showing more interest in cannabis-infused drinks. Established beverage companies as well as entrepreneurs are taking a close peek into formulas and methods for infusing CBD or THC or both into beverages.
  • Cannabis infused non-alcoholic beer is an emerging trend which is expected to gain significant traction, as companies focus on appealing the health-conscious pool of consumers. For instance, Grain wave is a THC-infused non-alcoholic beer that hit the dispensary shelves in December 2018.
  • The novelty of being able to drink THC-infused beverages has gained marked preference in the current adult-use recreational marijuana industry, especially for beverages that mimic beer or wine. While this trend gains pace, manufacturers are exploring the in-demand flavors to reinforce their product sales.

Cannabis Infused Drinks Market- Competitive Landscape

The competitive landscape of the cannabis infused drinks market continues to face the turmoil of regulations on the sales and consumption of cannabis. Cannabis infused drinks market in Canada is expected to grow at an impressive pace, in line with the existing favorable federal regulations that back the sales of cannabis in the region. Alcohol industry giants are buying into the ‘potent potable pot’ concept, however key issues prevail, such as the maze of laws that deal with beer and pot. Following the legalization of marijuana in Canada, beverage companies have increased the production of cannabis infused drinks in different flavors to tap growing demand from enthusiasts.

Source: https://webchronicletoday.com/2019/09/23/global-cannabis-infused-drinks-market-anticipated-to-accelerate-at-438-cagr-at-the-end-of-2029/

INTERVIEW: Empower Clinics $CBDT.ca JV Could Generate $US 30,000,000 In Annual Revenue From #CBD Extraction … But It Doesn’t End There $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 8:35 AM on Friday, September 20th, 2019

At 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for.  Add in the fact it is now on a ~ $USD 4,000,000 annualized revenue run rate for 2019 and it becomes the kind of company small cap investors have been dying to find as they watch pretender companies melt away.

But it doesn’t end there.  

CBD extraction has been a key element of the company’s vertical integration. Producing its’ own CBD products for its own patients just makes sense.  Up until a couple of days ago, it was a sound strategy that needed to be executed.  As of yesterday, execution arrived thanks to a JV with extraction experts Heritage Cannabis that will light up the Company’s 5,000 sq ft facility in Oregon.  Empower brings the infrastructure, Heritage brings the expertise and balance sheet.  The result is a match made in shareholder heaven with initial annual capacity of 6,000 Kg at ~ $US 5,000 per Kg, which adds up to $US 30,000,000 in potential revenue.

We emphasize potential  because nobody has started selling anything yet and the facility isn’t expected to begin producing for another 3-4 months.  However, with a built in patient database and talks already having commenced for white label products, Empower is on its way.  Moreover, “potential” cuts both ways, with capacity capable of increasing 2x – 3x without much trouble given the size of the facility.  

Can Empower successfully execute its extraction plan?  It’s a legitimate question, with a blow away answer..

The Company’s new CEO, Steven McAuley, who replaced the previous management team in January, is Six Sigma certified under the quality initiative of legendary GE chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never.

Grab your favourite beverage and settle in to watch what may be your next great small cap investment.

#Marijuana’s Biggest Day of the Year Is 4 Weeks Away! – SPONSOR: #NORTHBUD $NBUD.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 11:55 AM on Thursday, September 19th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

—————————————————–

Marijuana’s Biggest Day of the Year Is 4 Weeks Away

  • Last year, the marijuana industry made history… many times over.
  • But nothing took precedence over Canada becoming the first industrialized country in the world to legalize recreational cannabis, with sales commencing on Oct. 17, 2018.

Sean Williams Sep 19, 2019 at 6:06AM

Last year, the marijuana industry made history… many times over. But nothing took precedence over Canada becoming the first industrialized country in the world to legalize recreational cannabis, with sales commencing on Oct. 17, 2018. Even though Canada substantially trails the U.S. in terms of aggregate annual legal weed sales, it’s setting an example among industrialized countries that the legalization of marijuana is possible.

Now, the biggest date of 2019 is rapidly approaching. And wouldn’t you know it, it’s Oct. 17, once again.

Image source: Getty Images.

Why Oct. 17 is a big date for the pot industry (again)

Four weeks from today, laws governing the rollout of derivatives will officially go into effect in Canada. A derivative is an alternative cannabis consumption product that’s not already been approved.

Over the past 11 months and change, Canada has allowed for the sale of dried cannabis flower, cannabis oil, and sublingual sprays. Meanwhile, edibles, nonalcoholic cannabis-infused beverages, vapes, concentrates, and topicals, weren’t legal. This sort of two-step legalization process was done to allow the industry to find its footing, as well as give regulators time to adjust to cannabis becoming legal for adult purchase. But on Oct. 17, regulations now governing dried cannabis will apply to derivative products as well.

However, investors and Canadian consumers should understand that derivative pot products aren’t going to be showing up in dispensaries on Oct. 17. Much in the same way that it took dried cannabis flower brands weeks to begin populating dispensary store shelves, it’ll probably be the same story for derivative products. Regulatory agency Health Canada has cautioned that derivative supply won’t hit the market until mid-December, with it taking weeks or months thereafter for supply to be adequate to meet demand.

This, of course, is really big news for marijuana stocks, because derivative cannabis products are a considerably higher margin product for the industry, relative to dried flower. In select U.S. states (ahem, Oregon), we’ve witnessed the oversupply and commoditization of dried flower, leading to weaker margins for pot businesses. We’re highly unlikely to see oversupply and pricing concerns from derivatives anytime soon.

A point that is sometimes lost on this derivative launch is that these are products which speak to a younger generation of cannabis users. Not only are derivatives more attractive in the respect that they may not need to be smoked, but they’re going to attract potentially long-term customers to the industry.

Image source: Getty Images.

Growers go all-out for derivative production

Considering the importance of derivatives to cannabis stock margins, it’s not surprising to find that growers have been laser-focused on derivative production for a good portion of 2019.

Some growers, such as OrganiGram Holdings (NASDAQ:OGI), have chosen to set up a variety of in-house derivative options. During the company’s fiscal third quarter, OrganiGram announced that it’d be investing 15 million Canadian dollars into a line of fully automated equipment necessary to produce up to 4 million kilos of chocolate edibles per year. This coincides with OrganiGram’s 56,000-square-foot phase 5 expansion which, among other things, is targeted at extra space for derivative production and processing.

The company has also developed a nano-emulsification technology that can speed up the onset of the effects of cannabinoids. This product will first be introduced as a powder that can be added to beverages, but OrganiGram is also actively looking for a partner to help it develop an infused beverage product containing this proprietary technology.

Cronos Group (NASDAQ:CRON), and its investment partner Altria, are also eager to see the green flag wave on derivatives. Cronos Group’s peak annual output of nearly 120,000 kilos per year may not even be enough to place this brand-name pot stock among the top-10 growers. But that’s OK with Cronos, as it’s placed its attention almost entirely on derivative cannabis products.

For instance, Cronos and Altria will be working together to roll out an assortment of vape products. Altria is well-versed in the adult smoking market and should prove helpful in assisting Cronos Group’s marketing efforts and product launches (regarding vapes). Beyond vaping, Cronos Group will be leaning on its partnership with Ginkgo Bioworks to produce targeted cannabinoids at commercial scale, as well as other third-party extraction service providers.

Image source: Getty Images.

Speaking of extraction services, there may not be a smarter way of playing the derivatives craze than with third-party extraction providers. As an example, MediPharm Labs (OTC:MEDIF) only commenced its extraction operations during the fourth quarter. Despite this, MediPharm managed to turn a nominal operating profit of $0.01 per share in the second quarter. The company’s sales and profitability are set to soar as growers scramble for derivative exposure. Yet, MediPharm’s sales and profits should remain highly predictable with the company locking in contracts for an extended period of time. Soon enough, the company’s annual extraction capacity will hit 500,000 kilos.

The one thing to remember about the upcoming marijuana derivatives launch

While, on one hand, the launch of derivative products should be lauded by investors, there’s another side to this launch that everyone should be aware of.

As I alluded to earlier, Health Canada has cautioned that alternative consumption products aren’t going to immediately hit dispensary shelves once the green flag waves on Oct. 17. Rather, it’s going to take time before any sort of supply is built up in the marketplace, with a presumptive two-month gap between when derivative regulations going into effect and when derivative products will begin showing up in licensed stores.

But here’s the thing: Product showing up in stores doesn’t mean that the supply will be sufficient to meet demand. Similar to what we’ve been witnessing in the dried flower market, supply issues exist that are likely going to make it difficult for derivative products to find their way into dispensaries, at least in the early going.

Don’t get me wrong, I expect derivatives to push sales and margins higher for cannabis stocks across the board. However, I think it’s going to be multiple quarters before Health Canada resolves a number of supply issues, resulting in what could be weaker-than-expected sales in the months to come.

Make no mistake: Derivatives are the future of the cannabis industry. Just understand that the future isn’t going to happen overnight. Give this industry, and the rollout of derivatives, proper time to mature, and you won’t be disappointed.

Here’s The Marijuana Stock You’ve Been Waiting For
A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming.

Cannabis legalization is sweeping over North America – 10 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.

And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.

Because a game-changing deal just went down between the Ontario government and this powerhouse company…and you need to hear this story today if you have even considered investing in pot stocks.

Source: https://www.fool.com/investing/2019/09/19/marijuanas-biggest-day-of-the-year-is-4-weeks-away.aspx

As Canada gears up for #pot 2.0, more shortages are on the menu, bodes well for #NORTHBUD $NBUD.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 12:04 PM on Monday, September 16th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE

As Canada gears up for pot 2.0, more shortages are on the menu

  • Canada will add edibles, extracts and topicals to the list of legal cannabis products no later than Oct. 17.
  • Many analysts agree these products will generate better demand and margins than dried flower.
  • But the federal government has not yet issued regulations for the new formats, making it difficult for producers to prepare lest they unknowingly violate some rule.

By: Kristine Owram, Bloomberg News

Canada’s legalization of pot edibles later this year is facing an even more shambolic start than the dried flower market, which is still struggling to meet demand, according to industry players.

“At least that time we knew what the permissible product types were going to be and were already making them in the medical context,” said cannabis lawyer Trina Fraser, a partner at Brazeau Seller Law in Ottawa.

Canada will add edibles, extracts and topicals to the list of legal cannabis products no later than Oct. 17. Many analysts agree these products will generate better demand and margins than dried flower. But the federal government has not yet issued regulations for the new formats, making it difficult for producers to prepare lest they unknowingly violate some rule.

A spokeswoman for Health Canada declined to comment on when the regulations will be released.

In addition, a huge licensing backlog has built up at Health Canada, the government agency that oversees cannabis regulations. About 614 applications were waiting in the queue as of March 31.

“A full rollout amongst a nice wide array of producers and a wide array of these new product types is going to take time, literally years, because we have such a licensing backlog,” Fraser said.

Company Stockpiling

Canada’s market for edibles and other alternative pot produces will eventually be worth C$2.7 billion ($2 billion) annually, but consumers should expect “missteps, delays and frustration” in the early days, Deloitte said in a report published Monday. Jennifer Lee, Deloitte Canada’s cannabis national leader, estimated it will be a minimum of 24 months before the industry normalizes.

In the meantime, many pot companies are stockpiling, choosing to forgo revenue today to ensure they have enough supply for the new high-value products. This is exacerbating the shortage of dried flower, but executives say it’s worth it.

“We’ve made a very conscious effort to delay revenue,” said Chuck Rifici, chief executive officer of Auxly Cannabis Group Inc. Selling into the market today doesn’t build brand recognition because shelves are empty and consumers are buying whatever’s available, he added. “I would much rather save that product, get a multiple of margin on that brand and make sure that I have enough inventory.”

Lab Delays

This is proving to be a boon for extraction companies like Valens GroWorks Corp. Valens has contracts with many of the biggest pot companies, including Canopy Growth Corp., Hexo Corp. and Tilray Inc., to extract cannabis oil from their plants, which is then used for products like edibles and vape cartridges. It’s also investing heavily in its testing labs in the belief that Health Canada will have stringent regulations to ensure pesticides and other contaminants don’t make it into the new consumer products.

“Even in labs today there’s delays where people are waiting three weeks to a month to get lab results back and I think that will only get worse,” said Everett Knight, Valens’ executive vice president of strategy and investments.

Companies are also making big bets on what products will be in demand, with Canopy and Hexo leaning toward cannabis beverages and others toward vaping.

Be Prepared

“Why do I want an edible or a drink when I can have a vape?” Irwin Simon, interim CEO of Aphria Inc., said in an interview on the sidelines of a cannabis conference last month. “I see the margins and the opportunities there.”

Rifici at Auxly also believes vape pens will be “the most important category by far.” But there are many unanswered questions. For example, will the government require companies to engrave its mandatory THC warning symbol into the pen itself, or will a sticker suffice?

This is why Valens is offering its customers 196 different options for its white-label vape pens. “You’ve got to make sure you cover your bases and prepare for all the possibilities,” Knight said.

Despite the uncertainty, it’s better to be prepared even if plans and production lines have to be tweaked once the regulations come out, said Bruce Linton, CEO of Canopy, which is building a 197,000 square foot bottling plant for cannabis beverages in Smiths Falls, Ontario.

“We’re in a situation where it’s better to spend money to be ready than to save money and be late,” he said.

 Cannabis Canada is BNN Bloomberg’s in-depth series exploring the stunning formation of the entirely new – and controversial – Canadian recreational marijuana industry. Read more from the special series here and subscribe to our Cannabis Canada newsletter to have the latest marijuana news delivered directly to your inbox every day.

Source: https://www.bnnbloomberg.ca/as-canada-gears-up-for-pot-2-0-more-shortages-are-on-the-menu-1.1268844

North Bud Farms $NBUD.ca Restructures Proposed California Operations with Signing of Offer to Purchase 11-Acre Property in Salinas, California $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 4:42 PM on Thursday, September 12th, 2019
  • Entered into a land purchase agreement with the Qlora Group to acquire a fully operational Cannabis farm consisting of approximately 300,000 sq. ft. of greenhouse capacity located in Salinas, California. 
  • With the near 11-acre cultivation facility comes additional licenses for processing and distribution. 
  • Transaction is valued at USD$11 million.       

TORONTO, Sept. 12, 2019 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company”) is pleased to announce that Bonfire Brands USA, a wholly owned subsidiary of NORTHBUD, has entered into a land purchase agreement with the Qlora Group to acquire a fully operational Cannabis farm consisting of approximately 300,000 sq. ft. of greenhouse capacity located in Salinas, California.  With the near 11-acre cultivation facility comes additional licenses for processing and distribution.  The transaction is valued at USD$11 million.       

The facility in Salinas, California is currently licensed and operating a 60,000 sq. ft. greenhouse capable of producing 12,000 kg a year and holds the approval to expand up to approximately 300,000 sq. ft. of capacity with estimated yields of 60,000 kg a year.  This infrastructure will serve as the primary operation for Bonfire Brands USA within the state of California, which is considered to be the largest cannabis market in the United States.

“Over the past seven months we have observed an evolution in the California market,” stated Justin Braune, President of Bonfire Brands USA. “Many existing legacy operations have been unsuccessful in transitioning their businesses into the adult use market post January 1st, 2019. Supply issues and licensing time frames have caused widespread re positioning of market shares amongst many verticals. Since the creation of Bonfire, we have determined that the acquisition of strategic licensed infrastructure will provide Bonfire with the most efficient operational structure possible. By controlling the complete vertical in one location per state we will have the capacity to increase both our offerings and margins. This will enable us to further improve our own brands as well as we work with complementary partners over a wide spectrum of product segments.”

Transaction Terms
Bonfire Brands USA entered into the land purchase agreement effective September 9, 2019.   The purchase price of the land is USD$8M. As part of the 60-day escrow agreement Bonfire Brands USA will make an initial deposit of USD$500,000. The remaining USD$7.5M mortgage will be held by the seller at a fixed interest rate. Over the first 12 months, Bonfire Brands USA will make interest only payments before entering into a traditional principal and interest mortgage. Upon successfully transferring all licenses from Monterey Holdings to Bonfire Brands USA, the Company will issue a convertible debt note in the amount of CAD$2.5M.  The debt note will be redeemable in four equal installments to be paid in cash or common shares of NORTHBUD (valued at the 30-day VWAP of the common shares on the CSE) at the discretion of the note holder.  If the note holder chooses to redeem in cash, then the installment will be paid in monthly installments over a 3-month period.  Any issuance of common shares of NORTHBUD will be subject to receipt of applicable regulatory approvals, including that of the CSE, and standard restrictions on resale.

Upon closing of the real estate transaction, it is expected that Bonfire Brands USA will begin to immediately operate the facilities under an operations agreement until the license transfer is complete.

In addition, Bonfire Brands USA intends to acquire the remaining assets of the Qlora Group related to the brands “California Bud Co.” and “Live For The Day” (LFTD) in exchange for common shares of NORTHBUD. Qlora Group advises that the brands accounted for USD$4.5M in unaudited revenue in 2018.  This transaction is expected to take approximately six months to complete for a consideration of USD$500,000. 

The Transaction is a significant acquisition but will not result in a “Fundamental Change” pursuant to the policies of the CSE. NORTHBUD will be preparing the necessary corporate and securities filings in order to secure the required approvals for the Transaction.

NORTHBUD has agreed to pay up to 5% in finder fees to arm’s length parties in connection with the closing of the Transaction. The fee is payable in common shares of NORTHBUD.

The closing of the Transaction is conditional on the receipt by the parties of applicable corporate and regulatory approvals including that of the CSE.

U.S. Expansion Update
NORTHBUD is pleased to have solidified its California expansion strategy with this this proposed transaction with Qlora Group and in light of this development and other factors  NORTHBUD has agreed to mutually terminate the previously announced letters of intent regarding Eureka Vapor and Tanforan Ventures LLC.  Mr. Justin Braune, President of Bonfire Brands USA will lead all NORTHBUD’s U.S. operations.

“Over the past seven months we have been working diligently to complete these transactions, however, during this time the market in California has evolved significantly,” said Ryan Brown, CEO of NORTHBUD.  “When the opportunity to purchase licensed real estate in one of the most desired cultivation climates in the state presented itself, we felt that this was the best strategy to maximize revenue as well as protecting shareholder value. The acquisition of this property will provide NORTHBUD with larger revenue potential and significantly less dilution than the previous proposed transactions. We look forward to a potential collaboration with both companies in the future and wish them the best of success.” 

The Nevada Botanical Science LOI agreement is still in place and the Company will update shareholders on material progress related to that transaction in due course.

While the proposed transactions involving Nevada Botanical Science and Monterey Holdings are complementary, they are independent and the Company may ultimately proceed to close one, both or none of the proposed transactions, depending on market conditions and regulatory requirements.

Corporate Update
NORTHBUD is pleased to update shareholders that the Evidence of Readiness Package was submitted to Health Canada and upon issuance of a standard cultivation licence from Health Canada, NORTHBUD will be ready to begin Canadian operations. 

About North Bud Farms Inc.
North Bud Farms Inc., through its wholly owned subsidiary GrowPros MMP Inc., is pursuing a licence under The Cannabis Act.  The Company has built a state-of-the-art purpose-built cannabis production facility located on 135 acres of Agricultural Land in Low, Quebec, Canada. NORTHBUD through its wholly owned U.S. subsidiary, Bonfire Brands USA has entered into agreements to acquire assets in California and Nevada.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements and information included in this press release that, to the extent they are not historical fact, constitute forward-looking information or statements (collectively, “forward-looking statements”) within the meaning of applicable securities legislation.  Forward-looking statements, including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. This press release contains forward- looking statements including those relating to the entering into of the Definitive Agreement and closing of the Transaction with Qlora. Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements.  Such risks and uncertainties include, among others, the risk factors included in the Company’s final long form prospectus dated August 21, 2018, which is available under the Company’s SEDAR profile at www.sedar.com. Accordingly, readers should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

Mark Wahlberg, Sean #Diddy Combs and Jillian Michaels Join the #CBD Craze – SPONSOR: NORTHBUD $NBUD.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 2:43 PM on Thursday, September 12th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE

Mark Wahlberg, Sean ‘Diddy’ Combs and Jillian Michaels Join the CBD Craze

By Peter Dalton

  • The Alkaline Water Company announced recently that it had acquired AQUAhydrate which is a Los Angeles-based bottled water producer.
  • Company is backed by Wahlberg, Sean “Diddy” Combs, and celebrity personal trainer Jillian Michaels.
  • This acquisition was part of plans to launch several CBD-infused products in the future.

There is a huge demand in different formats of CBD and there is increased popularity in functional wellness beverages. CBD is the non-psychoactive compound of cannabis. Many claim that CBD reduces pain and inflammation, helps with sleep, reduces anxiety, among many other medical needs.

The jury is still out, however, as the FDA states that those claims are unproven scientifically.Wahlberg, however, stated that he and Combs were excited by the acquisition as well as the opportunity to sell CBD products. Their vision was to build a lifestyles company focused on health and wellness. Wahlberg also believes that AQUAhydrate and Alkaline brands fit nicely together and will support future innovations in flavors, sparkling, and CBD products.

While Wahlberg is excited, he has spoken differently about marijuana in the past. He claimed to have stopped using marijuana due to his children. He also warned Justin Beiber “to lay off the grass”

Source: https://timesofcbd.com/mark-wahlberg-sean-diddy-combs-jillian-michaels-cbd-craze/